Moleculin Biotech, Inc. (MBRX) — Financial statements
Income statement, balance sheet, and cash flow for Moleculin Biotech, Inc. — annual and quarterly history with growth and margin analysis.
| Metric (USD Millions) | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Revenue & Gross Profit | ||||||
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Cost of Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Gross Profit | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Operating Expenses | ||||||
| R&D Expenses | 16↓10.4% | 18↓9.0% | 19↑2.7% | 19↑31.6% | 14 | |
| General & Administrative Expenses | 9↑3.8% | 9↓12.3% | 10↓13.2% | 12↑37.6% | 8 | |
| Selling & Marketing Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| SG&A Expenses | 9↑3.8% | 9↓12.3% | 10↓13.2% | 12↑37.6% | 8 | |
| Other Expenses | 0.09↓28.6% | 0.13↓0.8% | 0.13↓2.3% | 0.13↓20.7% | 0.16 | |
| Operating Expenses | 25↓5.8% | 27↓10.1% | 30↓3.3% | 31↑33.4% | 23 | |
| Total Costs & Expenses | 25↓5.8% | 27↓10.1% | 30↓3.3% | 31↑33.4% | 23 | |
| Operating Results | ||||||
| Operating Income | -25↑5.8% | -27↑10.1% | -30↑3.3% | -31↓33.4% | -23 | |
| Depreciation & Amortization | 0.09↓28.6% | 0.13↓0.8% | 0.13↓2.3% | 0.13↓20.7% | 0.16 | |
| EBITDA | -25↑5.7% | -27↑10.1% | -30↑3.3% | -31↓33.8% | -23 | |
| EBIT | -25↑5.8% | -27↑10.1% | -30↑3.3% | -31↓33.4% | -23 | |
| Interest & Other Income | ||||||
| Net Interest Income | 0.11↓80.9% | 0.55↓59.8% | 1↑470.0% | 0.24↓21.6% | 0.31 | |
| Interest Income | 0.11↓80.9% | 0.55↓59.8% | 1↑470.0% | 0.24↓21.6% | 0.31 | |
| Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Non-Operating Income | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Other Income / Expenses | -8↓273.4% | 5↑3634.8% | -0.14↓108.5% | 2↓77.2% | 7 | |
| Income Before Tax | -34↓54.2% | -22↑26.9% | -30↓2.6% | -29↓82.6% | -16 | |
| Income Tax Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Net Income & EPS | ||||||
| Net Income from Continuing Operations | -34↓54.2% | -22↑26.9% | -30↓2.6% | -29↓82.6% | -16 | |
| Net Income from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Net Income | -34↓54.2% | -22↑26.9% | -30↓2.6% | -29↓82.6% | -16 | |
| Bottom-Line Net Income | -34↓54.7% | -22↑26.9% | -30↓2.6% | -29↓82.6% | -16 | |
| EPS (Basic) | -28.42↑82.0% | -158.00↑58.1% | -376.75↑1.0% | -380.50↓71.6% | -221.75 | |
| EPS (Diluted) | -28.42↑82.0% | -158.00↑58.1% | -376.75↑1.0% | -380.50↓71.6% | -221.75 | |
| Weighted Average Shares | 12↑8501.3% | 0.14↑74.3% | 0.08↑3.6% | 0.08↑6.4% | 0.07 | |
| Weighted Average Diluted Shares | 12↑8501.3% | 0.14↑74.3% | 0.08↑3.6% | 0.08↑6.4% | 0.07 | |
* All figures in Millions of USD, except per share data. Growth rates calculated Year-over-Year (YoY). Data source: SEC Filings.